MedX Seeks Extension to Complete Convertible Note Financing for Teledermatology Expansion

The latest update is out from MedX Health ( (TSE:MDX) ).

MedX Health Corp., a Canadian medical-technology firm, develops non-invasive skin-screening and teledermatology solutions built around its proprietary SIAscopy imaging technology and DermSecure cloud-based platform. Its cleared devices and software support early detection of skin cancer and broader digital dermatology and aesthetic applications across several international markets, differentiating the company through its ability to precisely image and analyze skin components.

The company has applied to extend by 30 days, to April 15, 2026, the period to complete further closings of its non-brokered private placement of Series IV Convertible Loan Notes on the TSX Venture Exchange. Following an initial $2.7 million closing, MedX expects to raise up to an additional $2.3 million under the 6% notes, which are convertible into equity units, with proceeds earmarked for redeeming earlier Series I notes, advancing its DermSecure and SIAscopy platform, supporting an occupational health market launch, and general corporate needs.

The placement terms, including equity conversion features and agent compensation in the form of cash commissions and warrants, are designed to attract accredited investors while potentially strengthening MedX’s capital structure through future share issuances. Anticipated insider participation, conducted under applicable minority protection rules, underscores internal confidence in the company’s strategy as it seeks funding to scale its teledermatology technology and deepen its presence in the occupational health and broader digital dermatology sectors.

More about MedX Health

MedX Health Corp. is a Canadian data-enabled medical technology company specializing in non-invasive skin screening and teledermatology via its proprietary SIAscopy imaging technology and DermSecure platform. The company targets early detection of skin cancer and the expansion of digital dermatology and skin care services for clinical, investigational, and beauty and aesthetics markets across multiple regulated jurisdictions including Canada, the U.S., Europe, Australia, New Zealand, the U.K., and Turkey.

Its Health Canada, U.S. FDA, TGA, and CE-cleared products enable pain-free, accurate imaging of skin lesions for rapid dermatologist review through a secure, cloud-based patient management system. SIAscopy is positioned as a differentiated technology, capable of simultaneously and non-invasively measuring melanin, hemoglobin, and collagen distribution in the epidermis and dermis, underpinning MedX’s telemedicine offering for faster assessment of suspicious moles, lesions, and other skin conditions.

Average Trading Volume: 91,677

Technical Sentiment Signal: Sell

Current Market Cap: C$18.04M

See more data about MDX stock on TipRanks’ Stock Analysis page.